Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$11.01
-$0.24(-1.31%)
At close: 4:00 PM EST
$11.01
-$0.24(-1.31%)
Day’s Range― - ―
52-Week Range$7.21 - $20.46
Previous CloseN/A
Volume407.39K
Average Volume (3M)5.00M
Market Cap
$2.07B
Enterprise Value$2.02B
Total Cash (Recent Filing)$138.15M
Total Debt (Recent Filing)$204.41M
Price to Earnings (P/E)13.0
Beta0.87
Next Earnings
Aug 12, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding231,772,720
10 Day Avg. Volume4,006,565
30 Day Avg. Volume5,003,948
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.96
Enterprise Value/Gross Profit6.46
Enterprise Value/Ebitda9.11
Forecast
1Y Price Target
$19.67Price Target Upside78.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.83
Revenue Forecast (FY)$560.02M
Bulls Say, Bears Say
Bulls Say
High Margins And Free Cash Flow GenerationSustained high gross and net margins with substantial operating and free cash flow provide durable funding for manufacturing scale, R&D (including SG-001), debt service and opportunistic buybacks. Strong cash conversion shields operations during reimbursement or demand variability.
Rapid ASCENIV Commercial AdoptionFast ASCENIV uptake and record new patient starts reflect durable commercial traction for a differentiated specialty IVIG. A growing high-margin franchise reduces reliance on commodity IG sales, supports better mix and makes revenue more resilient to standard IG price competition.
Regulatory Expansion Of ASCENIV LabelFDA pediatric label expansion broadens ASCENIV's addressable population and allows earlier intervention in treatment, strengthening long-term market penetration and prescribing behavior. Regulatory success de-risks commercial expansion and increases sustainable demand.
Bears Say
Sharp BIVIGAM Revenue DeclineA >50% decline in BIVIGAM shows exposure to volatile distributor ordering and competitive displacement. Material weakness in a legacy product line creates durable revenue concentration risk if standard IG share loss persists and limits ability to fully offset with specialty growth.
Elevated Days Sales Outstanding (DSO)Sustained high DSOs tie up cash and raise working capital needs, reducing liquidity available for investment or debt reduction. If channel inventory or payer timing remains extended, cash conversion could lag profits and force greater reliance on borrowings or slower reinvestment.
Withdrawal Of Longer-term GuidanceWithdrawing long-term guidance signals structural uncertainty around pricing, channel dynamics and competitive entrants. Reduced visibility complicates capital allocation, hinders long-horizon planning for capacity or R&D, and can constrain strategic investment pacing.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $2.07B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on May 06, 2026. The company reported $0.171 earnings per share for the quarter, missing the consensus estimate of $0.193 by -$0.022.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.18.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 231,772,720 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.171 in its last earnings report, missing expectations of $0.193. Following the earnings report the stock price went down -15.972%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (78.63% Upside)
$19.67 (78.63% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $250.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.66%
12-Months-Change
Fundamentals
Return on Equity
38.97%
Trailing 12-Months
Asset Growth
30.28%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed materially positive operational and financial momentum driven by ASCENIV — including strong revenue growth (+28% YoY), substantial margin expansion (71% gross margin vs 53% prior year), improved adjusted EBITDA (+24% YoY), and robust cash generation (~$58M in Q1) — alongside strategic balance sheet actions and pipeline progress (pediatric label expansion and SG-001 preclinical work). Offsetting these positives were significant near-term headwinds in the standard IG market: BIVIGAM revenue declined sharply (-54% YoY) due to distributor ordering disruption and aggressive competitor discounting (ASP erosion of ~15%–20%), elevated channel inventory and DSOs (~107 days), and withdrawal of longer-term guidance. Overall, the company appears financially resilient and operationally well-positioned, with the performance of ASCENIV and strong cash/margin metrics outweighing the transitory channel and pricing pressures in the standard IG segment.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$19.67
▲(78.63% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
3.36% Insiders
25.89% Mutual Funds
<0.01% Other Institutional Investors
39.09% Public Companies and
Individual Investors